Sensiblex 40 mg/ml Solution for Injection for Cattle

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
13-02-2023

Aktiivinen ainesosa:

Denaverine Hydrochloride

Saatavilla:

Veyx-Pharma GmbH

ATC-koodi:

QG02CX90

INN (Kansainvälinen yleisnimi):

Denaverine Hydrochloride

Lääkemuoto:

Solution for injection

Prescription tyyppi:

POM-V - Prescription Only Medicine – Veterinarian

Terapeuttinen ryhmä:

Cattle

Terapeuttinen alue:

Neurological Agent uterine relaxant

Valtuutuksen tilan:

Authorized

Valtuutus päivämäärä:

2017-06-15

Valmisteyhteenveto

                                Revised: September 2022
AN: 00358/2022 & 00360/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Sensiblex 40 mg/ml solution for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Denaverine hydrochloride 40.0 mg (equivalent to 36.5 mg Denaverine)
EXCIPIENTS:
Benzyl alcohol (E1519)
20.0 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection
Clear, colourless solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (cows, heifers)
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cows, heifers:
-
Promotes dilation of the soft tissues of the birth canal in cases
where the birth
canal is insufficiently opened.
-
Regulates
uterine
contractions
during
parturition
in
animals
with
hypertonic
muscular contractions of the uterus.
Heifers:
-
Promotes dilation of the soft tissues of the birth canal to facilitate
parturition.
4.3
CONTRAINDICATIONS
Do not administer in cases of mechanical obstetrical obstructions.
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
Revised: September 2022
AN: 00358/2022 & 00360/2022
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The product is ineffective if no part of the foetus has already
entered the cervical
canal and if abdominal pressing has not started.
Before administering the product it is important to ensure there are
no mechanical
obstructions (e.g. oversized foetus, malpresentation, uterine
torsion). If present,
obstructions must be removed prior to product administration (e.g.
correction of
abnormal presentation or uterine torsion).
Signs of peripartum electrolyte imbalances (with special attention to
calcium and
phosphorus), as well as metabolic disturbances (e.g. ketosis), both
possibly causing
weak labour and thus insufficient dilation of the soft birth canal,
require particular
consideration and supportive measurements.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in
                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia